Projects & Publications (Select since 2010)

Codeine-induced mortality in breastfed infants:

Smolina K, Weymann D, Morgan S. Ross C, Carleton B.  Association between regulatory advisories and codeine prescribing to postpartum women.   Jama. 2015 May: 313(18):1861-2. PMID: 25965237

Baber M, Chaudhry S, Kelly L, Ross C, Carleton BC, Koren G. The pharmacogenetics of codeine pain relief in the postpartum period. Pharmacogenomics J. 2015 Oct;15(5):430-5. PMID: 25752520.

Kelly LE, Chaudhry SA, Rieder MJ, ‘t Jong G, Moretti ME, Lausman A, Ross C, Berger H, Carleton B, Hayden MR, Madadi P, Gideon K. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLOS ONE. 2013 Jul;8(7):e70073. PMID: 23922910

Lam J, Kelly L, Matok I, Ross CJ, Carleton BC, Hayden MR, Madadi P, Koren G. Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. Ther Drug Monit. 2013 Aug;35(4):466-472. PMID: 23783165

Lam J, Matlow JN, Ross CJ, Hayden MR, Carleton BC, Madadi P. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: The devil is in the details. Ther Drug Monit. 2012 Aug;34(4):378-80. PMID: 22777151

Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer MLA, Nauta M, Carleton BC, Koren G, Hayden MR. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012 Apr;91(4):692-9. PMID: 22398969

Lam J, Kelly L, Ciszkowski C, Landsmeer ML, Nauta M, Carleton BC, Hayden MR, Madadi P, Koren G. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr. 2012 Jan;160(1):33-7. PMID: 21880331

VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit. 2011 Aug;33(4):425-32. PMID: 21743374

Madadi P, Ross CJD, Hayden MR, Carleton BC, Gaedigk A, Leeder SJ, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009 Jan;85(1):31-5. PMID: 18719619

Codeine-induced mortality in toddlers after surgery:

Velez de Mendizabal N, Jimenez-Mendez R, Cooke E, Montgomery C, Dawes J, Jacobo-Cabral CO, Gonzalez-Ramirez R, Castaneda-Hernandez G, Carleton BC. A compartmental analysis for morphine and its metabolites in young children after a single oral dose. Clin Pharmacokinet. 2015 Oct;54(10):1083-90. PMID: 25773480

Khetani JD, Madadi P, Sommer DD, Reddy D, Sistonen J, Ross CJ, Carleton BC, Hayden MR, Koren G. Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome. Pediatr Drugs. 2012 Dec;14(6):411-415. PMID: 23013460

Kelly LE, Rieder M, van den Anker J, Malkin B, Ross CJ, Neely MN, Carleton BC, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012 May;129(5):e1343-7. PMID: 22492761

Codeine-induced mortality:

Lam J, Woodall KL, Solbeck P, Ross CJ, Carleton BC, Hayden MR, Koren G, Madadi P. Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Sci Int 2014 Jun;239:50-6. PMID: 24747667

Madadi P, Sistonen J, Silverman G, Gladdy R, Ross CJ, Carleton BC, Carvalho JC, Hayden MR, Koren G. Life-threatening adverse events following therapeutic opioid administration in adults: Is pharmacogenetic analysis useful? Pain Res Manag. 2013 May-June;18(3):133-6. PMID: 23748253

Shaw K, Amstutz U, Jimenez-Mendez R, Ross CJ, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther Drug Monit. 2012 Apr;34(2):121-3. PMID: 22406651

Madadi P, Hildebrant D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJD, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G. Fatal hydrocodone overdose in child: pharmacogenetics and drug interactions. Pediatrics. 2010 Oct;126(4):e986-9 PMID: 20837591

Cisplatin-induced hearing loss in the treatment of cancer:

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC. SLC16A5 genetic variation confers protection from cisplatin-induced ototoxicity in adult testicular cancer patients. JAMA Oncology. 2017 Apr [Epub ahead of print] PMID: 28448657

Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dube MP, Hayden MR. Genetic markers of cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2014 Sep;96(3):296-8. PMID: 25141953

Castelán-Martínez OD, Jiménez-Méndez R, Rodríguez-Islas F, Fierro-Evans M, Vázquez-Gómez BE, Medina-Sansón A, Clark P, Carleton B, Ross C, Hildebrand C, Castañeda-Hernández G, Rivas-Ruiz R. Hearing loss in Mexican children treated with cisplatin. Int J Pediatr Otorhinolaryngol. 2014 Sep;78(9):1456-60. PMID: 25037447

Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR. Response to “Evaluation of pharmacogenetic markers to predict the risk of cisplatin-induced ototoxicity.” Clin Pharmacol Ther. 2014 Aug;96(2):158. PMID: 24755913

Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Letter to the editor “Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.” Clin Pharmacol Ther. 2014 Mar;95(3):253. PMID: 24193170

Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Feroz-Zada Y, Dube MP, Carleton BC, Hayden MR; CPNDS Consortium. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013 Aug;94(2):243-51. PMID: 23588304

Dionne F, Mitton C, Rassekh R, Brooks B, Ross CJ, Hayden MR, Carleton BC. Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics J. 2012 Jun;12(3):205-13. PMID: 21502965

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; the CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009 Dec;41(12):1345-9. PMID: 19898482

Anthracycline-induced heart failure in the treatment of cancer:

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015 Sep;47(9):1079-84.PMID: 26237429

Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ; CPNDS consortium. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015 Jul;16(10):1065-76. PMID: 26230641

Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; the CPNDS Consortium. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer.  2013 Aug;60(8):1375-81. PMID: 23441093

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May;30(1):1422-8. PMID: 2190010

Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. J Cardiovasc Pharmacol. 2011 Sep;58(3):228-39. PMID: 21386709

Ross CJ, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol. 2011 Mar;18:e134-51. PMID: 21467604

Warfarin-induced bleeding:

Aminkeng F. Using pharmacogenetics in real time to guide therapy: the warfarin example. Clin Genet. 2014 Jun;85(6):533-4. PMID: 24628520

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder SJ, Hayden M, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Ped Blood Cancer. 2014 Jun;61(6):1055-62. PMID: 24474498

Carleton BC. Gene-based warfarin dosing. Ther Drug Monit. 2010 Jun;32(3):332 PMID: 20498559

Drug-induced serious skin reactions:

Amstutz U, Ross CJD, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC. HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013 Jul;94(1):142-9. PMID: 23588310

Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton BC, Papaluca-Amati M, Demoly P, Shear NH. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther. 2011 Jun;89(6):896-901. PMID: 21562486

Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton BC. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol. 2011 Mar;18:e106-20. PMID: 21467602

Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011 Mar;18:e121-33. PMID: 21467603

Ito S, Carleton BC. Predictive genotype for carbamazepine-induced severe skin reactions. CMAJ. 2010 May 18;182(8):804. (Letter) PMID: 20479057

Beta-interferon induced liver injury in the treatment of MS patients:

Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf. 2014 Oct;13(10):1305-17. PMID: 25134421

Kowalec K, Carleton BC and Tremlett H. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2013 Jul;2(3):183-192. PMID: 25877724

Kowalec K, Yoshida EM, Traboulsee A, Carleton BC and Tremlett H. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Mult Scler Relat Disord. 2013 Jan;2(1):57-59. PMID: 25877455

Safety of inhaled corticosteroids (ICS) in patients treated for asthma and cystic fibrosis:

Smy L, Shaw K, Amstutz U, Smith A, Berger H, Carleton B, Koren G. Hair cortisol as a hypothalamic-pituitary-adrenal axis biomarker in pregnant women with asthma: a retrospective observational study. BMC Pregnancy Childbirth. 2016 Jul 20;16(1):176 PMID 27440139

Smy L, Shaw K, Smith A, Russell E, Van Uum S, Rieder M, Carleton B, Koren G. Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children. Pediatr Res. 2015 Jul;78(1):44-7.  PMID: 25790275

Pharmacogenomic Diversity and Drug Safety in World-wide Populations:

Wright G, Carleton B, Hayden M, Ross C. The global spectrum of protein-coding pharmacogenomics diversity.  Pharmacogenomics J. 2016 Oct 25. PMID: 27779249 [Epub ahead of print]

Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J. 2014 Apr;14(2):160-170. PMID: 23588107

Brunham LR, Chan SL, Li R, Aminkeng F, Liu X, Saw WY, Ong RT, Pillai EN, Carleton BC, Toh D, Tan SH, Koo SH, Lee EJ, Chia KS, Ross CJ, Hayden MR, Sung C, Teo YY. Pharmacogenomic diversity in Singaporean populations and Europeans. Pharmacogenomics J. 2014 Dec;14(6):555-563. PMID: 24861855

Chan SL, Samaranayake N, Ross CJ, Toh MT, Carleton BC, Hayden MR, Teo YY, Dissanayake VH, Brunham LR.  Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: Implications for clinical implementation of pharmacogenomics.  Pharmacogenet Genomics. 2016 Jan;26(1):28-39. PMID: 26444257

Clinical Practice Guidelines / Recommendations:

Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC and the CPNDS clinical recommendations group.  Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. PMID: 27197003

Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC and the CPNDS clinical recommendations group.  Clinical Practice Recommendations for the Management and Prevention of Cisplatin-induced Hearing Loss using Pharmacogenomics Markers. Ther Drug Monit. 2016 Aug;38(4):423-31. PMID: 26960170

Shaw K, Amstutz U, Kim R, Lesko LJ, Rhoades J, Turgeon J, Michaud V, Hwang S, Ito S, Carleton BC and the CPNDS clinical recommendations group. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 variants in Warfarin Therapy.   Ther Drug Monit. 2015 Aug;37(4):428-36.  PMID: 26186657

Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC, the CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014 Apr;55(4):496-506. PMID: 24597466

Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC, CPNDS Clinical Recommendations Group. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol. 2013 Nov; 20(3): e369-e396. PMID: 24214521

Amstutz U, Carleton BC. Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther. 2011 Jun;89(6):924-7. PMID: 21508939